You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Medtronic
Express Scripts
Mallinckrodt
McKesson

Last Updated: August 6, 2020

DrugPatentWatch Database Preview

Cediprof Inc Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for CEDIPROF INC, and what generic alternatives to CEDIPROF INC drugs are available?

CEDIPROF INC has three approved drugs.

There is one US patent protecting CEDIPROF INC drugs.

There are eight patent family members on CEDIPROF INC drugs in seven countries.

Summary for Cediprof Inc
International Patents:8
US Patents:1
Tradenames:3
Ingredients:3
NDAs:3

Drugs and US Patents for Cediprof Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-012 Dec 8, 2003 AB1,AB2,AB3 RX No No   Start Trial   Start Trial
Cediprof Inc METHYLPHENIDATE HYDROCHLORIDE methylphenidate hydrochloride TABLET;ORAL 208737-002 Feb 1, 2019 DISCN No No   Start Trial   Start Trial
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-008 Mar 1, 2002 AB1,AB2,AB3 RX No No 6,399,101   Start Trial   Start Trial
Cediprof Inc METHYLPHENIDATE HYDROCHLORIDE methylphenidate hydrochloride TABLET;ORAL 208737-001 Feb 1, 2019 DISCN No No   Start Trial   Start Trial
Cediprof Inc DEXMETHYLPHENIDATE HYDROCHLORIDE dexmethylphenidate hydrochloride TABLET;ORAL 209211-002 Sep 19, 2018 AB RX No No   Start Trial   Start Trial
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-006 Mar 1, 2002 AB1,AB2,AB3 RX No No 6,399,101   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Cediprof Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-006 Mar 1, 2002 6,399,101   Start Trial
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-001 Mar 1, 2002 6,399,101   Start Trial
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-003 Mar 1, 2002 6,399,101   Start Trial
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-005 Mar 1, 2002 6,399,101   Start Trial
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-011 Mar 1, 2002 6,399,101   Start Trial
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-010 Mar 1, 2002 6,399,101   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Medtronic
McKinsey
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.